Dr. Greg Marchand Named to the Fulbright Specialist Roster by the U.S. Department of State
FOR IMMEDIATE RELEASE
MESA, Ariz. — August 13, 2022
We are delighted to announce that two of our research papers, “Meta-Analysis of Veress Needle Entry Versus Direct Trocar Entry in Gynecologic Surgery” and “Meta-Analysis Of Laparoscopic Radical Hysterectomy Vs. Robotic Assisted Radical Hysterectomy For Early Stage Cervical Cancer” have been accepted for oral presentation at the AAGL Global Congress in Aurora, Colorado in December 2022. Most of our research staff plans on attending, and we hope to see many of our old and new friends at the conference!
About Dr. Greg Marchand
Greg J. Marchand, MD, FACS, FACOG, FICS, is a dual board-certified obstetrician-gynecologist and minimally invasive gynecologic surgeon practising in Mesa, Arizona. He holds the ABOG Focused Practice Designation in Minimally Invasive Gynecologic Surgery and directs the Marchand Institute for Minimally Invasive Surgery, a 501(c)(3) tax-exempt non-profit research and educational corporation (EIN 42-2857240). He is Program Director of an SLS-accredited fellowship in Minimally Invasive and Robotic Gynecologic Surgery, holds three issued United States patents, and has served as Principal Investigator on eight FDA clinical trials. His systematic reviews are prospectively registered with PROSPERO, reported to PRISMA standards and appraised with the Cochrane Risk of Bias 2 tool. He accepts no industry funding for his research.
Media Contact
Maria A. Sainz
Director of Communications and Media Relations
maria@marchandobgyn.com
(480) 999-0905
Newsroom and press kit · Full publication list · Research methodology · Expert commentary topics
###
Related posts
